Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis
Blood Adv
.
2024 Feb 13;8(3):549-552.
doi: 10.1182/bloodadvances.2023011698.
Authors
Narendranath Epperla
1
,
Qiuhong Zhao
1
,
Tamara Moyo
2
,
Marcus P Watkins
3
,
Montreh Tavakkoli
4
,
Celeste Bello
5
,
Pallawi Torka
6
7
,
Nishitha Reddy
8
,
Colin Thomas
9
,
Kaitlin Annunzio
1
,
Beth Christian
1
,
Stefan K Barta
4
,
Geoffrey Shouse
10
,
Adam J Olszewski
11
,
Nancy L Bartlett
3
Affiliations
1
Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
2
Department of Medicine, Levine Cancer Center, Atrium Health, Charlotte, NC.
3
Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
4
Department of Medicine, University of Pennsylvania, Philadelphia, PA.
5
Department of Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
6
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY.
7
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
8
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
9
Department of Medicine, Thomas Jefferson University, Philadelphia, PA.
10
Department of Medicine, City of Hope National Medical Center, Duarte, CA.
11
Department of Medicine, Brown University Providence, RI.
PMID:
38091577
PMCID:
PMC10835265
DOI:
10.1182/bloodadvances.2023011698
No abstract available
MeSH terms
Adenine
Humans
Lymphoma, B-Cell, Marginal Zone* / pathology
Piperidines
United States
Substances
ibrutinib
Adenine
Piperidines
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States